Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900056/S229

ROTAPRO Rotational Atherectomy System

Boston Scientific Corp · Decision date Oct 21, 2026

MEDTECHLEDGER EXPLANATIONP900056/S229

What did the FDA decide?

The FDA recorded a 30-day notice decision, coded OK30, dated 2026-10-21 for supplement P900056/S229 to Boston Scientific Corp's ROTAPRO Rotational Atherectomy System, a coronary atherectomy catheter under product code MCX in the Cardiovascular specialty. The recorded supplement reason is a process change affecting a manufacturer, sterilizer, packager or supplier.

The stated scope is approval of changes to printed circuit board assembly (PCBA) soldering and strain relief fixtures for the system. This is a supplement-level decision on manufacturing fixtures, not a new approval of the whole device, and the source record gives no detail on the fixture changes, their validation or any effect on finished-device performance. No supporting documents were included, so the basis for the decision cannot be checked from this record alone.

FDA approval order statement

approval for changes to PCBA soldering and strain relief fixtures for ROTAPRO Rotational Atherectomy System
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 21, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P900056/S229
Regulatory pathway
PMA supplement
Product code
MCX
Decision code
OK30
Decision date
Oct 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: CATHETER, CORONARY, ATHERECTOMY.

Product code
MCX
FDA device class
3

For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900056/S229 received

    Application receipt date recorded by FDA.

  2. P900056/S228 · Related supplement

    ROTAPRO Rotational Atherectomy System

  3. P900056/S226 · Related supplement

    ROTAPRO Rotational Atherectomy Systems

  4. P900056/S229 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900056

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMay 28, 1993FDA
Boston Scientific CorpPMA supplementOct 20, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
Two Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records